Innate Pharma (NASDAQ:IPHA) Upgraded at Zacks Investment Research
According to Zacks, “Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company’s commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France. “
A number of other analysts have also commented on the company. Svb Leerink reissued an outperform rating on shares of Innate Pharma in a report on Monday, November 11th. HC Wainwright reissued a buy rating on shares of Innate Pharma in a report on Tuesday, November 26th.
An institutional investor recently bought a new position in Innate Pharma stock. Oxford Asset Management LLP acquired a new position in Innate Pharma S.A. (NASDAQ:IPHA) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 44,226 shares of the company’s stock, valued at approximately $284,000. Oxford Asset Management LLP owned 0.06% of Innate Pharma at the end of the most recent reporting period.
Innate Pharma Company Profile
Innate Pharma SA, a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for cutaneous T-cell lymphomas; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications and tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.
Featured Article: Using other technical indicators with support levels
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.